PBM
SCYX icon

Propel Bio Management’s SCYNEXIS SCYX Stock Holding History

Propel Bio Management’s Portfolio SCYX Stock Details SCYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
+543,478
New +$3.37M 1.16% 24

Other funds holding SCYX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HCM
Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Propel Bio Management's SCYX Position: Q2 2026 in Review

Propel Bio Management opened a new position in SCYNEXIS (SCYX) in Q2 2026: 543,478 shares worth $2.21M. The stake represents 1.16% of the portfolio and ranks #24 among its holdings.

28 funds tracked by Wall St. Rank hold SCYX as of Q2 2026.

  • Propel Bio Management held 543,478 shares of SCYNEXIS worth $2.21M as of Q2 2026.
  • SCYNEXIS was a new Propel Bio Management position in Q2 2026.
  • SCYNEXIS made up 1.16% of Propel Bio Management's portfolio in Q2 2026, its #24 holding.
  • 28 funds tracked by Wall St. Rank held SCYNEXIS as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.